An observational study in Extensive Stage Small Cell Lung Cancer, sponsored by Hebei Medical University Fourth Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-27.
Sponsored by Hebei Medical University Fourth Hospital · Observational
The purpose of this study is to assess efficacy and safety of patients who receive Adebrelimab combined with chemotherapy±chest radiotherapy as first-line treatment of extensive stage small cell lung cancer in the real world.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,558 are open to participants now.
This study's planned enrollment of 50 is below the median of 189 across 1,512 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Hebei Medical University Fourth Hospital is the lead sponsor of 78 studies on the registry; 53 are open to participants now.
Counted across the registry records on this site, refreshed daily.
extensive stage small cell lung cancer
Exclusion Criteria:
Drug: Adebrelimab + chemotherapy · Radiation: ±chest radiotherapy
Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
Chest radiotherapy: 3Gy/15f-18f or 2Gy/20f-25f
Progression free survival (PFS)
Baseline to measured date of progression or death from any cause
Time frame: evaluated in 24 months since the treatment began
Objective response rate (ORR)
Baseline to measured stable disease
Time frame: tumor assessment every 6 weeks since the treatment began，up to 24 months
Disease control rate (DCR)
Baseline to measured progressive disease
Time frame: tumor assessment every 6 weeks since the treatment began，up to 24 months
Duration of Overall Response（DoR）
The duration of overall response is measured from the time that measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented
Time frame: tumor assessment every 6 weeks since the treatment began，up to 24 months
Overall survival (OS)
Baseline to measured date of death from any cause
Time frame: the first day of treatment to death or last survival confirm date,up to 24 months
Adverse events
Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. The number of Participants with adverse events will be recorded at each treatment visit
Time frame: up to 24 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hebei Medical University Fourth Hospital